Last reviewed · How we verify
GSK Biologicals' 719125 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GSK Biologicals' 719125 (GSK Biologicals' 719125) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK Biologicals' 719125 TARGET | GSK Biologicals' 719125 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK Biologicals' 719125 CI watch — RSS
- GSK Biologicals' 719125 CI watch — Atom
- GSK Biologicals' 719125 CI watch — JSON
- GSK Biologicals' 719125 alone — RSS
Cite this brief
Drug Landscape (2026). GSK Biologicals' 719125 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-biologicals-719125. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab